Bristol-Myers Squibb Company (NYSE:BMY) reached 6.8% versus a 1-year low price of $42.48. The stock was last seen -0.07% lower, reaching at $45.37 on 7/26/2019. At a recent session, the prices were hovering between $44.26 and $46.11. This company shares are 22.06% off its target price of $55.38 and the current market capitalization stands at $74.26B. The recent change has given its price a -1.48% deficit over SMA 50 and -28.76% deficit over its 52-week high. The stock witnessed 1% gains, -1.13% declines and -7.28% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BMY’s volatility during a week at 3.1% and during a month it has been found around 1.89%.

What Does Bristol-Myers Squibb Company (BMY) Do?

The company describes itself in regulatory filings as, “Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.” [Text can be found here: https://www.marketwatch.com/investing/stock/BMY/profile under company description.]

Bristol-Myers Squibb Company (BMY) Top Holders

Institutional investors currently hold around $58.38 billion or 80.3% in BMY stock. Look at its top three institutional owners: Vanguard Group Inc owns $6.01 billion in Bristol-Myers Squibb Company, which represents roughly 8.09% of the company’s market cap and approximately 10.3% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 125,535,748 shares of the stock are valued at $5.7 billion. The third largest holder is Blackrock Inc., which currently holds $4.88 billion worth of this stock and that ownership represents nearly 6.58% of its market capitalization.

Bristol-Myers Squibb Company 13F Filings

At the end of March reporting period, 886 institutional holders increased their position in Bristol-Myers Squibb Company (NYSE:BMY) by some 168,399,508 shares, 806 decreased positions by 88,598,369 and 224 held positions by 1,030,000,000. That puts total institutional holdings at 1,287,000,000 shares, according to SEC filings. The stock grabbed 175 new institutional investments totaling 27,027,566 shares while 118 institutional investors sold out their entire positions totaling 8,214,326 shares.

Bristol-Myers Squibb Company (NYSE:BMY) Insider Trades

Multiple company employees have indulged in significant insider trading. Bristol-Myers Squibb Company disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Samuels Theodore R. II has acquired 5,000 shares of Bristol-Myers Squibb Company (BMY) in the trading session dated May. 16, 2019. These shares are worth $236,450 and were traded at $47.29 each. The SEC filing shows that Santiago Karen Murphy performed a sale of 3,065 shares. The Controller disposed these shares by way of transaction on May. 16, 2019. The company’s shares were given away at $47.56 per share worth to an income of some $145,771 to the account of Santiago Karen Murphy.

Director, Paliwal Dinesh C, purchased 9,540 common shares of Bristol-Myers Squibb Company (BMY) in the open market. In a transaction dated Apr. 30, 2018, the shares were bought at an average price of $52.4, giving away a sum of $499,896. After this purchase, 12,935 common shares of BMY are directly owned by the insider, with total stake valued at $586,877.

In the transaction dated Apr. 30, 2018, a great number of shares acquired came courtesy the Director; Paliwal Dinesh C added a total of 4,770 shares at an average price of $52.4, amounting to approximately $249,948. The insider now directly owns 8,027 shares worth $364,167.

Bristol-Myers Squibb Company (BMY) Analyst Guide

Several analysts have released their opinion on Bristol-Myers Squibb Company (NYSE:BMY), with 3 analysts believing it is a strong buy. Whereas 6 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.27 average brokerage recommendation [T1].